Related Experiment Video
Updated: Oct 11, 2025

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Effectiveness of granulocyte colony-stimulating factor for patients with acute-on-chronic liver failure: a
Wei Huang1, Yuanji Ma1, Lingyao Du1
1From the Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Background:
The safety and efficacy of granulocyte colony-stimulating factor (G-CSF) for the treatment of acute-on-chronic liver failure (ACLF) remain uncertain. Therefore, we conducted a meta-analysis to draw a firmer conclusion.
Methods:
We searched the Cochrane library, PubMed, Embase, and China Biology Medicine disc to identify relevant RCTs performed before January 2020. Risk ratios (RRs) and their 95% confidence intervals (95% CIs) were calculated using a random effects model.
Main Outcome Measures:
RRs (95% CI) for 1-, 2-, and 3-month survival rates.
Sample Size:
Six RCTs, including three open-label studies.
Results:
The six studies included 246 subjects (121 in a G-CSF group and 125 in a control group). G-CSF administration significantly improved the 1-, 2-, and 3-month survival rates in patients with ACLF. The pooled RRs (95% CI, P) were 0.43 (0.27-0.69, P=.0004), 0.44 (0.32-0.62, P<.00001), and 0.39 (0.22-0.68, P=.0009), respectively.
Conclusion:
G-CSF may be beneficial and effective in the treatment of ACLF, but further studies are needed to verify this conclusion.
Limitations:
The sample size was small, and studies were restricted to countries in Asia.
Prospero Registration Number:
CRD42021225681 CONFLICT OF INTEREST: None.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Regulation of Hematopoietic Stem Cells
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

